Company ProfilePremium

Atomo Diagnostics Limited

Company Profile Analysis

Ticker: AT1.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Atomo Diagnostics Limited - Company showcase

Year Founded & Workforce

2010

Atomo Diagnostics Limited logo

Atomo Diagnostics Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Atomo Diagnostics Limited Overview

Atomo Diagnostics is a micro-cap Australian medical device company that designs, makes and sells integrated, blood-based lateral-flow rapid diagnostic test (RDT) devices for professional point-of-care and self-testing. It has two revenue engines. The first is its own finished tests, chiefly the WHO-prequalified, TGA-approved and CE-marked Atomo HIV Self-Test, sold through Viatris (formerly Mylan) into Global Fund–financed low- and middle-income country (LMIC) programmes, through NFLD in Europe, and through pharmacies and government programmes in Australia and New Zealand. The second is an OEM "Atomo inside" business supplying its patented all-in-one Pascal cassette to diagnostics partners. The flagship OEM customer is Lumos Diagnostics, whose FebriDx bacterial-versus-viral test received US FDA CLIA waiver in March 2026 on the Pascal platform. With FY2026 revenue of A$5.3m (+41%), a narrowing loss, no debt and a pipeline spanning active syphilis, liver function (ALT) and ferritin, Atomo is a sub-scale but differentiated device-platform play. It is in a leadership transition and depends on regular equity raises.


Company's own description (FY2026 Annual Report and Results Overview). The FY2026 Directors' Report defines the group's principal activity as "the development and sale of medical devices." The FY2026 Results Overview calls Atomo "a commercial stage diagnostic company with a growing revenue base from sales of approved professional and self-test point-of-care tests (POCT) across global markets." It says Atomo's solutions deliver usability and reliability that enable decentralised testing. The company describes two businesses:

  1. Atomo Point of Care Test (POCT) Diagnostic Products. Blood-based rapid tests sold into professional-use and self-test channels globally. The stated focus is a pipeline of "high value, reimbursed diagnostic products for decentralised professional testing."

  2. Point of Care Test Technologies (OEM Business). Partner sales driven by an FDA-approved, CLIA-waived test (Lumos FebriDx). Atomo supplies an integrated proprietary all-in-one device (Pascal) to partners seeking better usability and performance for blood-based POCT, plus "additional technologies that can integrate with the client's own cassette" (the Florey clip-in device).

The company's ASX boilerplate describes it as an Australian-headquartered medical device company supplying integrated RDT devices to the global diagnostic market. Its patented devices simplify testing, improve usability and improve reliability for point-of-care and at-home testing.

Business model and revenue model. Atomo generates revenue in four reported lines (FY2026 Annual Report, Note 3):

By nature, revenue is overwhelmingly product sales. Sale of goods was A$5.23m (98.0%) in FY2026. Services, meaning development and licence fees recognised over time, were A$0.11m (2.0%). There is no subscription revenue. Licensing revenue is episodic: FY2025 included roughly A$340k of one-off licence fees. In the OEM channel, Atomo is paid a transfer price for each Pascal cassette. Management describes Atomo as receiving "a percentage portion of the proceeds based on the transfer price of Pascal" for each FebriDx test sold to PHASE Scientific (FY2026 Results Overview).

The P&L is also materially supported by non-revenue government income. FY2026 other income was A$2.23m, comprising the R&D tax rebate (A$1.26m), CRC-P grant income for the Active Syphilis test (A$0.89m) and interest (A$0.08m). That equals 42% of revenue.

Value-chain position. Atomo sits at the device design and manufacturing layer of the rapid-diagnostics value chain:

  • It designs and patents the integrated device: lancet, blood collection, buffer delivery and test strip housed in one cassette.

  • It qualifies tooling, including high-cavitation injection moulds now being qualified, and runs proprietary blister packaging machines. Blister Machine #2 was relocated to an Atomo-operated facility in Sydney in FY2026.

  • It performs finished-test assembly and packaging at its South African branch.

  • It relies on third-party manufacturers for certain inputs (FY2026 risk disclosures).

  • For own products, it holds regulatory registrations (TGA, CE/IVDD/IVDR, WHO PQ) and sells through distributors such as Viatris, NFLD, pharmacy wholesalers and government programmes.

  • For OEM products, the partner (e.g., Lumos) owns the assay and regulatory file, and Atomo is the "critical supplier" of the device.

Customer types. Global health procurement intermediaries (Viatris, funded by the Global Fund); European consumer-health distributors (NFLD; historically supplying retailers such as Boots and Tesco); Australian and New Zealand pharmacies and wholesalers (Chemist Warehouse online, CDC in New Zealand); Australian government-funded programmes (e.g., distribution with NAPWHA, the National Association of People with HIV Australia); and IVD companies buying OEM devices (Lumos Diagnostics, Chromacare, an unnamed UK company, and two new OEM customers from January 2026). Customer concentration is extreme: five customers accounted for 92.0% of FY2026 revenue (FY2025: 72.5%). The largest single customer ("Customer E") accounted for 36.2%. The Annual Report does not name it, but given the nine-fold rise in Lumos orders it is likely Lumos; that attribution is an inference.

End-markets served. (i) HIV self-testing and professional HIV testing (LMIC public health, European retail, Australia/NZ pharmacy and government); (ii) US decentralised professional testing (urgent care, physician office) via CLIA-waived OEM products; (iii) emerging sexual health (active syphilis), liver function monitoring (ALT) and iron deficiency (ferritin); (iv) historically, COVID-19 antibody testing (FY2020–FY2022) and female health/pregnancy.

Independent characterisation. Atomo is best understood as a device-platform company with a small captive finished-goods franchise. Its intellectual property is ergonomic and mechanical, not biochemical: it solves the user-error problem in finger-stick blood testing. The economic proof point is the FDA CLIA waiver for FebriDx. US trials showed more than 99% concordance between trained and untrained users, and management states the waiver relied on Pascal's performance. That regulatory precedent is arguably Atomo's most valuable asset, because it gives future partners a predicate path into the CLIA-waived and self-test channels. CLIA waiver can expand a rapid blood test's addressable market more than ten-fold (company claim). The business remains sub-scale, however: revenue of A$5.3m, gross margin of 35%, and statutory operating cash burn of A$3.4m in FY2026. Volumes are lumpy and tied to partner order cycles and donor-funded tenders.

Strategy

Stated strategic themes (FY2026 Annual Report, "Likely developments"; FY2026 Results Overview).

  1. Grow HIV self-testing globally. Continue rollout in developed markets (Europe, Australia, New Zealand) and LMIC programmes. Targets: Australian pharmacy count 6× and NZ 8× over three years.

  2. Expand the POC cassette supply (OEM) business, especially in the US. Use the FebriDx CLIA waiver as "a predicate pathway for new Diagnostics partners" seeking CLIA-waived and self-test access. This includes promoting Pascal to US test developers.

  3. Grow development services. Atomo is paid to develop custom products and solutions for partners.

  4. Improve operating margins. Bring blister manufacturing in-house and qualify high-cavitation tooling to reduce COGS.

  5. Build the own-product pipeline. Active Syphilis (clinical trials from early CY2027) and ALT Liver (partnering in FY2027), using non-dilutive grants and selective in-licensing "to support lower-cost development and go to market."

  6. Capital discipline. "Remaining focused on conserving capital over the medium term."

  7. Leadership repositioning. "Strategic priority shifts from foundation-building to scale: accelerating adoption, expanding partnerships and maximising the value of Atomo's differentiated platform" (FY2026 Results Overview, "New chapter").

Management's virtuous-cycle framing: revenue growth → improved operating leverage → reinvestment in R&D → broader product portfolio → long-term revenue growth and enterprise value. Management expects revenue "to cover most non-research operating costs."

Initiatives announced in the last 24 months.

Sustainability/ESG commitments. None quantified. The board is "considering on an ongoing basis" a climate-risk response.

Medium-term financial targets/guidance. No quantitative revenue, margin or EBITDA guidance has been issued. Qualitative guidance: "We expect the underlying revenue trajectory to continue into FY27 and beyond." When announcing the March 2026 raise, the company stated it was "funded through early 2028." That statement assumed a raise of up to A$4.0m; only ~A$3.05m was raised before shortfall placement.

Products & Services

Atomo markets its devices under the "AtomoRapid" umbrella. Products are organised below by the company's two businesses. Pricing is not publicly disclosed for any product.

5A. Atomo POCT Diagnostic Products (own finished tests)

ProductDescription and key capabilitiesTarget customer / channelRegulatory statusLaunch / latestCommercial notes
Atomo HIV Self-Test (flagship)Integrated all-in-one finger-stick blood RDT detecting HIV-1/2 antibodies; built-in lancet, blood collector and buffer; designed for untrained lay usersLMIC public health via Viatris (Mylan brand) funded by the Global Fund; Europe via NFLD (historically Boots and Tesco in the UK); Australia via pharmacies (196 active as at July 2026), Chemist Warehouse e-commerce (Oct 2025) and government-funded programmes including NAPWHA; New Zealand pharmacies (73 activated) and CDC wholesalerWHO prequalified; TGA approved (described pre-IPO as the only TGA-approved HIV self-test); CE markedLaunched South Africa late 2016; ongoingFY2026 HIV revenue A$2.84m (+21%). NAPWHA demand +275% over 24 months. Targets: Australian pharmacies 6× and NZ pharmacies 8× over 3 years (FY2026 Results Overview).
AtomoRapid HIV 1&2 (professional use)Same integrated platform for clinician point-of-care HIV screeningClinics, community testing, Australia and EuropeTGA approval Nov 2020; CE markedAustralian launch early CY2021Revenue reported within point-of-care tests; not separately disclosed
Active Syphilis Test (pipeline)Rapid blood test intended to distinguish active from prior syphilis infection on the Pascal format; optimised for self-testing. Company states sensitivity above 85% for active syphilis detection is market-leading.Sexual health clinics, public health buyers, existing HIV self-test channelsPre-registration. Development and initial verification complete; technology transfer to manufacturing Q4 FY2026–Q1 FY2027; clinical trials from early CY2027; initial regulator engagement completedTargeted post-CY2027 trialsFunded partly by A$2.44m CRC-P grant (A$0.84m held as deferred grant revenue at 30 June 2026). South Africa assembly accreditation being extended to syphilis tests.
ALT Liver Function Test (pipeline)Rapid test measuring alanine aminotransferase (ALT) for liver damageInitial use cases: monitoring patients on drugs at risk of causing liver injury (DILI), clinical-trial monitoring, doctor-prescribed at-home monitoring, fatty liver disease screeningEarly development; exclusive in-licence from an undisclosed licensor (Q2 FY2026)Development commenced FY2026Seeking pharma/CRO/commercial partners and government funding in FY2027
Tests under considerationStroke (acute neurological triage), HCV, HBV, HIV 4th generation, cardiacProfessional decentralised marketsConcept / commercial assessment—Subject to commercial assessment (FY2026 Results Overview)
AtomoRapid COVID-19 antibody test (legacy)Blood-based COVID-19 IgG/IgM antibody testSupplied via NG Biotech (France/UK) and Access Bio (US)TGA approved Aug 20202020–2022Drove FY2021–FY2022 revenue; demand ended post-pandemic
Female health / early pregnancy (legacy / partner)Application cited in company boilerplateConsumer———

5B. Point of Care Test Technologies (OEM business)

Platform / productDescription and key capabilitiesTarget customerStatusCommercial notes
Pascal integrated cassette (flagship OEM device)Patented all-in-one cassette integrating lancet, blood sampling, buffer delivery and partner's test strip. Validated in US clinical trials (FebriDx) with more than 99% concordance between trained and untrained users.IVD companies with lateral-flow assays seeking CLIA waiver or self-test claimsCommercialFY2026 OEM revenue A$2.15m (+209%). Atomo is exclusive licensor, manufacturer and supplier of Pascal for FebriDx. Supply arrangement with Lumos runs to June 2031.
— Lumos FebriDx (on Pascal)Partner's host-response test differentiating bacterial from non-bacterial (viral) acute respiratory infectionUS urgent care and decentralised reimbursed professional testingFDA CLIA waiver granted (announced 27–30 March 2026)FY2026 Pascal orders for FebriDx of ~A$1.9m, nine-fold increase on FY2025. Lumos–PHASE contract valued at up to ~US$316–317m of FebriDx revenue over six years, subject to MOQs. At the CLIA waiver, Atomo said the agreement points to Pascal revenue of ~US$3.4m (basis per 30 March 2026 announcement).
— Chromacare ferritin test (on Pascal)Rapid test for iron levels (iron deficiency screening), professional and at-homeCanadian partner ChromacareValidation / registration; Chromacare interested in a US CLIA waiver using Pascal FebriDx as predicateInitial order ~A$170k in FY2026; long-term supply agreement anticipated early FY2027
— UK customer novel test (on Pascal)Undisclosed novel rapid test addressing a large unmet clinical need in professional settingsUnnamed UK companyValidation / registration20,000 Pascal units ordered in FY2026; commercial supply agreement anticipated early FY2027
— Two new OEM customers (Jan 2026)Undisclosed applicationsUndisclosedOrders completed by Q4 FY2026Company says these support long-term supply agreements anticipated early FY2027
Florey clip-in deviceAdd-on technology that integrates with a client's own cassette to turn it into a user-friendly blood-based POCT systemIVD companies with existing cassettesPresented at two US POC diagnostics conferences (Oct 2025)No disclosed revenue
Development servicesPaid development of custom products and solutions using Atomo technologyPartnersOngoingDevelopment and licence fees: A$0.54m in FY2025 (incl. ~A$340k one-off licences); A$0.11m in FY2026

Financial Narrative

Data provenance. FY2025 and FY2026 figures are from the audited FY2026 Annual Report. FY2022–FY2024 income statement data are from the Kalkine/TradingView aggregator (based on annual reports). FY2024 net loss, EPS and closing equity are cross-checked to the FY2026 Annual Report (statutory performance table and statement of changes in equity). Blank cells = not publicly disclosed in sources reviewed. EBITDA rows are labelled by basis. The aggregator reports FY2025 cost of revenue of A$2.00m and gross profit of A$1.79m, while the audited FY2026 Annual Report comparatives show A$1.87m and A$1.92m; the audited figures are used and the discrepancy is noted.

Income statement

Notes: FY2024 underlying EBITDA of approximately -A$4.5m is drawn from a third-party summary of the company's FY2026 historical EBITDA chart (Stockwire). FY2026 statutory operating loss = loss before tax (A$3.51m) less finance costs (A$0.015m). Weighted average shares were 647.1m in FY2025 and 827.3m in FY2026.

Margins and growth

Revenue CAGR. FY2022 to FY2026 (4 years): -18.9% per year, distorted by the COVID peak in FY2022. FY2023 to FY2026 (3 years): +28.0% per year. FY2021 to FY2026 (5 years, from A$6.72m): -4.5% per year.

Commentary. FY2022 was a COVID-driven peak, with revenue of A$12.3m from antibody test devices supplied to partners. FY2023 brought the cliff: revenue fell 79% to A$2.5m, gross margin compressed to 26% on under-absorbed fixed costs, and the net loss widened to A$10.0m. FY2024 to FY2026 shows a deliberate three-year restructuring. Overheads were cut every year. Operating expenses fell a further ~A$0.64–0.78m (about 9%) in FY2026, with professional fees nearly halved from A$0.95m to A$0.49m and employee costs down 12% to A$2.88m. The net loss narrowed from A$6.85m to A$4.97m to A$3.51m.

The FY2026 inflection is revenue-led: +41%, with OEM revenue tripling on Lumos FebriDx orders. But mix worked against margin. Low-priced Global Health HIV volumes and the absence of FY2025's one-off licence income pushed gross margin back to 35%. The "underlying EBITDA" improvement to -A$2.06m benefits materially from a 47% increase in other income (R&D rebate plus grant). Excluding other income, the operating loss before D&A would be roughly A$4.3m, broadly unchanged from FY2025's roughly A$4.9m on the same basis. That is an analyst calculation from statutory lines. The quality of the improvement is therefore mixed: real revenue traction, but not yet operating leverage on product gross profit.

Balance sheet

Commentary. The balance sheet is clean but small. There are no borrowings and no financing facilities (Note 21), and the company remains "debt free." Intangibles are being amortised down; no additions were made in FY2026, and A$0.80m of development costs were impaired historically. PP&E fell to A$0.34m as plant reached the end of its depreciable life, with A$7.2m gross plant against A$7.1m accumulated depreciation. Capacity investment (high-cavitation moulds, the second blister line) is therefore likely to require capex in FY2027.

Receivables almost doubled to A$3.22m. Within this, trade receivables rose to A$1.84m, 95% aged 0–30 days, reflecting a strong Q4 sales quarter, and the R&D rebate receivable was A$1.08m. Cumulative losses of A$68.5m against A$75.8m contributed capital show the extent of value consumption since founding. Unrecognised tax losses have a tax effect of A$9.34m.

Cash flow

Commentary. Operating cash burn worsened in FY2026 (-A$3.37m versus -A$1.96m) even as the P&L loss narrowed. Three factors drove this: (i) working capital build, with receivables up A$1.62m and inventory up A$0.32m; (ii) lower customer receipts, because FY2025 had benefited from collections and A$1.07m of upfront grant cash recorded as deferred revenue; and (iii) a decline in deferred revenue (-A$0.23m). Management's own presentation frames total cash receipts as A$10.2m, but that figure includes A$4.0m of equity proceeds. Funding has come entirely from equity: A$1.65m in FY2025 and A$4.06m in FY2026. At the FY2026 operating burn rate, year-end cash of A$3.71m represents roughly 13 months of runway before any working-capital release (analyst calculation).

Ratios (analyst calculations from audited figures; FY2025 ROA uses year-end assets because FY2024 total assets were not available)

ROIC, net debt/EBITDA and interest coverage are not meaningful: the company is loss-making, has net cash, and its only interest cost is lease interest of A$14.7k. The long cash conversion cycle reflects raw material stockholding (A$1.73m of the A$1.97m inventory is raw materials) relative to a small cost base. The FY2026 DSO is inflated by Q4 revenue of A$2.3m.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Product line revenue (AUD Mn)

Product line revenue (AUD Mn)FY2024FY2025FY2026

Point-of-care tests (HIV finished tests)

—2.3492.840

Point-of-care technology (OEM / Pascal)

—0.6952.151

Development and licence fees

—0.5440.106

Other revenue

—0.2040.237

Total revenue

4.0903.7925.334

Product line YoY growth and mix (%)

Product line YoY growth and mix (%)FY2025 mixFY2026 mixFY2026 YoY growth

Point-of-care tests (HIV)

62.053.320.9

Point-of-care technology (OEM)

18.340.3209.4

Development and licence fees

14.32.0-80.5

Other revenue

5.44.416.2

Total

100.0100.040.6

Group Entities

EntityCountryOwnershipLikely function (analyst characterisation)

Atomo Diagnostics Limited

Australia

Parent (listed)

Holding, HQ, IP, R&D

Atomo Australia Pty Limited

Australia

100%

Operating entity

Atomo South Africa (branch of Atomo Australia Pty Ltd)

South Africa

100%

Finished test assembly and packaging; warehouse

Atomo Limited

United Kingdom

100%

European commercial presence

Atomo US Inc.

United States

100%

US presence

Atomo Operations US LLC

United States

100%

US operations

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (AUD Mn)

12.342.544.093.795.33

Cost of sales (AUD Mn)

8.091.882.651.873.45

Gross profit (AUD Mn)

4.250.671.441.921.88

Other income incl. R&D rebate and grants (AUD Mn)

———1.522.23

Depreciation and amortisation (AUD Mn)

2.001.891.661.581.43

EBIT, aggregator basis (AUD Mn)

-5.69-11.21-7.78-5.84—

Operating loss before finance costs, statutory (AUD Mn)

———-4.95-3.50

Underlying EBITDA, company-reported (AUD Mn)

——-4.50-3.38-2.06

Pre-tax income (AUD Mn)

-5.71-9.96-6.85-4.97-3.51

Net income (AUD Mn)

-5.72-9.96-6.85-4.97-3.51

EPS basic (AUD cents)

——-1.08-0.768-0.425

EPS diluted (AUD cents)

——-1.08-0.768-0.425

Dividends per share (AUD cents)

00000

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue growth YoY (%)

83.6-79.461.0-7.340.6

Gross margin (%)

34.426.435.250.635.2

Underlying EBITDA margin (%)

——-110.0-89.2-38.6

Net margin (%)

-46.4-392.1-167.5-131.1-65.9

Balance Sheet and Share Count (M)

MetricFY2024FY2025FY2026

Total assets (AUD Mn)

—9.2810.83

Cash and equivalents (AUD Mn)

3.693.223.71

Trade and other receivables (AUD Mn)

—1.693.22

Inventories (AUD Mn)

—1.651.97

Short-term debt incl. current leases (AUD Mn)

—0.160.26

Long-term debt incl. non-current leases (AUD Mn)

—0.030.12

Borrowings excl. leases (AUD Mn)

—00

Net debt incl. leases (AUD Mn, negative = net cash)

—-3.03-3.34

Total equity (AUD Mn)

10.086.987.71

Goodwill (AUD Mn)

—00

Intangible assets (AUD Mn)

2.071.641.22

Working capital, current assets less current liabilities (AUD Mn)

—4.405.97

Accumulated losses (AUD Mn)

60.0964.9568.47

Shares on issue (M)

—739.1902.4

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Receipts from customers (AUD Mn)

———5.144.62

R&D rebate and government grants received (AUD Mn)

———1.831.54

Operating cash flow (AUD Mn)

———-1.96-3.37

Capex, PP&E (AUD Mn)

———0.030.04

Free cash flow (AUD Mn)

———-1.99-3.40

Lease repayments (AUD Mn)

———0.190.24

Net equity raised (AUD Mn)

———1.654.06

Dividends paid (AUD Mn)

00000

Buybacks (AUD Mn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2025FY2026

ROE (%) — net loss / average equity

-58.3-47.9

ROA (%)

-53.6-35.0

Current ratio (x)

3.033.04

Debt (leases) / equity (x)

0.030.05

Asset turnover (x)

0.410.53

Days sales outstanding (trade receivables)

60126

Days inventory outstanding

322208

Days payables outstanding

74111

Cash conversion cycle (days)

308223

Currency-denominated financial assets (AUD Mn)

Currency-denominated financial assets (AUD Mn)FY2025FY2026

US dollar

0.480.88

South African rand

0.250.84

Pound sterling

0.210.26

New Zealand dollar

0.010.03

Euro

0.010.01

Valuation Snapshot

MetricValueSource

IPO price (Apr 2020)

A$0.20

StartupDaily

Post-IPO high

A$0.565 (20 Apr 2020)

Biotech Daily

Latest observed price

~A$0.018 (late Aug / early Sep 2026)

InvestSMART

Change since IPO

approx. -91%

Calculated

52-week range

~A$0.02–0.06 (rounded)

Halo Technologies

Price at CLIA waiver / placement announcement

A$0.040 (30 Mar 2026); placement priced at A$0.033

InvestSMART; ASX

Price change since placement

approx. -45% from A$0.033; -55% from A$0.040

Calculated

Fiscal-year share price change (%)

FY2024

FY2025

Share price change per Remuneration Report

14-44

Valuation Multiples

MultipleAtomo

P/E

Not meaningful (loss)

EV/EBITDA

Not meaningful (negative EBITDA)

EV/Sales (FY2026)

~2.4x

P/B (FY2026 equity A$7.71m)

~2.1x

Price/NTA

Net tangible assets per share per Appendix 4E reported as 0.72 cents (unit as published)

Share Price & Returns

DateTypePrice (AUD)Shares (M)Gross proceeds (AUD Mn)Attaching options

Apr–Aug 2025 (incl. FY2026 tranches)

Placement and SPP shortfall

0.0185

71.1 (FY2026 portion)

1.29 (FY2026 portion)

1:1 at A$0.04, 3-year expiry

Mar–Apr 2026

Placement

0.03390.93.00

1:2 at A$0.045, 2.5-year expiry

May 2026

SPP

0.0331.350.04

1:2 at A$0.045

Analyst Conclusions

Management guidance. No quantitative guidance. Management expects the underlying revenue trajectory "to continue into FY27 and beyond," driven by HIV, OEM/Pascal and new products. It expects revenue to cover most non-research operating costs. Near-term milestones it has flagged: long-term Pascal supply agreements with the UK customer, Chromacare and two new OEM customers (early FY2027); Active Syphilis clinical trials (early CY2027); ALT partnering (FY2027); qualification of capacity and COGS projects. Consensus growth expectations: not publicly available.

Bull case.

  1. FebriDx becomes a high-volume US product. The Lumos–PHASE contract is valued at up to ~US$316m over six years with MOQs, and every test needs a Pascal cassette. FY2026 Pascal orders already rose nine-fold to ~A$1.9m before a full post-waiver year. A ramp could make OEM the majority of revenue with recurring, contract-backed volume to 2031.

  2. The CLIA predicate converts into a multi-partner platform. Chromacare, the UK customer and two new OEM customers could sign supply agreements in early FY2027. Each additional waived or self-test product on Pascal adds volume with minimal Atomo R&D cost, improving mix and gross margin.

  3. Operating leverage plus cheap valuation. At an EV of ~A$13m (~2.4x FY2026 sales), a debt-free company growing revenue 41%, narrowing underlying EBITDA losses 39%, and moving blistering in-house could re-rate sharply if it nears EBITDA breakeven within two years.

Bear case.

  1. Funding treadmill and dilution. FY2026 operating burn of A$3.37m roughly equals year-end cash of A$3.71m. The March 2026 "funded through early 2028" claim assumed A$4.0m, but the SPP raised just A$44.5k. With 230m options largely out of the money and the share price ~45% below the latest placement, further raises at depressed prices look likely.

  2. Concentration and margin fragility. Five customers make up 92% of revenue, and gross margin fell from 51% to 35%. FebriDx volumes depend on Lumos (itself a small-cap) and PHASE executing a US launch, and LMIC HIV volumes depend on donor funding. A delay at either could reverse FY2026's growth.

  3. Leadership and governance gap. The founder-CEO and chief technologist left abruptly in August 2026. The interim CEO's term is six months, the board has three members, and the only committee includes the CEO. Execution risk is elevated just as the company tries to convert partners into contracts.

Key catalysts and monitorables (next 12 months).

Concluding analyst verdict.

Atomo Diagnostics exits FY2026 in better commercial shape than at any point since the COVID-19 boom. Revenue rose 41% to A$5.3m, the OEM line tripled, and the net loss fell for a third straight year to A$3.5m. The FDA's March 2026 CLIA waiver for Lumos's FebriDx, granted on the strength of Pascal's lay-user performance, is a genuine strategic asset. It turns Atomo from a one-product HIV self-test vendor into a credentialled device platform with a contracted US volume channel to 2031 and a regulatory predicate that third parties are already exploring.

The financial base remains fragile, however. Gross margin fell to 35% as low-priced global health volumes grew. Statutory operating cash burn increased to A$3.4m, close to the A$3.7m cash balance. Almost half of "underlying EBITDA" improvement came from R&D rebates and grant income rather than product economics. Five customers generate 92% of sales. The retail shareholder base largely declined the May 2026 SPP, and the share price trades well below the March placement. Into this the board has introduced a founder-CEO transition, with an interim leader on a six-month term.

Our synthesis is that Atomo is a high-risk, binary-leaning micro-cap whose equity value hinges on three verifiable events over the next 12 months: (1) observable FebriDx volume ramp through Lumos and PHASE; (2) conversion of at least two OEM validation customers into signed supply agreements; and (3) a credible permanent CEO and financing on terms that limit dilution. If all three occur, an EV of ~2.4x trailing sales for a debt-free, 40%-growth device platform looks undemanding. If FebriDx stalls or financing is struck at distressed prices, dilution will likely absorb much of the operational progress. Investors should treat the stock as an option on Pascal's platform economics, size positions accordingly, and track quarterly 4C cash flows and the Lumos order book as the primary indicators.


Source list (primary documents first)

  • Atomo Diagnostics, 2026 Appendix 4E and Annual Report (FY ended 30 June 2026), released 31 August 2026

  • Atomo Diagnostics, FY26 Results Overview presentation, 31 August 2026

  • Atomo Diagnostics, ASX announcement "Managing Director & CEO Transition," 19 August 2026

  • Atomo Diagnostics, Quarterly Activities / Appendix 4C reports: 29 October 2025, 28 January 2026, 28 April 2026, 23 July 2026

  • Atomo Diagnostics, H1 FY26 Appendix 4D, Half Year Report and Results Presentation, 26 February 2026

  • Atomo Diagnostics, ASX announcements: 15 January 2026 and 30 January 2026 (HIV Self-Test orders); 25 March 2026 (price query response); 30 March 2026 (FebriDx CLIA waiver; capital raise); 17 April 2026 (Aware Letter response); 15 May 2026 (SPP results); 29 October 2025 (commercial progress)

  • Atomo Diagnostics, FY2025 results call transcript (via financialfilings.com)

  • Kalkine / TradingView financial summary (FY2021–FY2025); Kalkine company report (2020)

  • InvestSMART announcement summaries and share price data; Market Index; Simply Wall St ownership data; multiples.vc; Investing.com; Halo Technologies; MarketScreener; IBISWorld

  • StartupDaily, Biotech Daily, SmallCaps and Stockhead (IPO-era history, 2020); Stockwire and ShareCafe (FY2026 coverage); TipRanks (board changes)

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedIndependenceBackground and educationCommitteeShares / options held

Patrick Cook

Non-Executive Chair

Director 2 May 2025; Chair 9 Sep 2025

Independent

35+ years as senior executive in medical devices and POC diagnostics; former NED/Chair of Workplace Drug Testing Australasia and eWaste Connection; former board member, Prostate Cancer Foundation of Australia (Qld); FAICD; degrees in Science and Marketing

Audit and Risk Committee member

717,909 shares; 1,940,541 options

Dr Cheri Walker

Executive Director and Interim CEO

Director 15 Nov 2022; Interim CEO 19 Aug 2026

Not independent (executive since 19 Aug 2026)

25+ years in life sciences and diagnostics; former CEO Zeta Corporation; founder-CEO Rhinostics; CFO Kailos Genetics; senior roles at Abcam, Charles River Labs, Qiagen and Life Technologies (now Thermo Fisher); BA Biology (Swarthmore College); PhD Human and Molecular Genetics (Baylor College)

Audit and Risk Committee member (Chair until 19 Aug 2026)

Nil shares; 1,000,000 options

Anthony May

Non-Executive Director

2 May 2025

Independent

Director roles at Hoechst (Germany), Microgenics (USA), Fisher Scientific and Thermo Fisher Scientific; experience across public and private pathology and IVD sales/management; member of the Australasian Association for Clinical Biochemistry and Laboratory Medicine; BSc

Chair, Audit and Risk Committee

540,541 shares; 1,240,541 options

Executive Leadership Team

NameTitleTenurePrior roles / notes

Dr Cheri Walker

Interim CEO (6-month initial term, extendable by 6 months)

Since 19 Aug 2026

See above. Annualised interim CEO remuneration A$445,000 plus A$50,000 director fee; 90-day notice.

Chandra Sukumar

Chief Operating Officer

Since 31 Oct 2016

Base A$265,000 plus super; STI up to 30% of base

Mathew Watkins

Company Secretary

Since 9 Jun 2024

Chartered Accountant; Australian Market Lead, Vistra Australia

CFO / finance lead

Not a KMP; FY2025 results presented by "Suzy" (surname not disclosed)

——

John Kelly (former)

Co-founder, MD and CEO

1 Apr 2010 – 19 Aug 2026

Ex-COO Unilife (2005–08); ResMed New Product Implementation Group lead; CR Bard Europe. Hons BEng Mechanical Engineering (Liverpool); MSc Manufacturing Systems Engineering (Queen's University Belfast); Executive MBA (University of Sydney). NED of Tetratherix Limited. Holds 74,111,870 shares (~8.2% of shares on issue at 30 June 2026).

“—” = not publicly disclosed.

Directors' Remuneration

NameSalary and feesCash bonusSuperLong service leaveShare-basedTotal FY2026Total FY2025

Patrick Cook (Chair)

43,75000040,63284,3824,167

Cheri Walker (NED in FY2026)

50,00000029,02379,02350,000

Anthony May

39,06304,688020,31664,0674,167

John Kelly (MD/CEO)

396,96928,71030,00020,2710475,950425,791

Chandra Sukumar (COO)

274,01559,62530,00010,1450373,785316,857

Total KMP

803,797

88,335

64,688

30,416

89,971

1,077,207

1,042,648

Board & Management Changes

DateChangeContext

2 May 2025

Cook and May appointed; John Keith (Chair), Paul Kasian and Deborah Neff resign

Board renewal to "lean up the board" and support reduced opex (FY2025 results call)

23 May 2025

Kelly appointed Interim Chair

Continuity pending independent chair

9 Sep 2025

Cook appointed Chair; Kelly steps down as Interim Chair

Governance normalisation

19 Aug 2026

Kelly steps down as MD/CEO and director; Walker appointed Interim CEO

Board decision to "reposition" executive leadership closer to US and European markets; formal global CEO search commenced

—

NED "C LaBelle" resigned (Final Director's Interest Notice)

—

Major Shareholders

HolderSharesApprox. % of 902.4m sharesBasis / date

GZ Family Holdings Pty Ltd

89,895,644

~10.0

Simply Wall St register data (2025); substantial holder history from 2023

John Kelly (co-founder, former MD)

74,111,870

~8.2

FY2026 Annual Report (KMP disclosure)

Dalraida Holdings Pty Limited

65,120,000

~7.2

Simply Wall St (2025)

Global Health Funds, Inc. (Global Health Investment Fund)

~61,570,716

~6.8

Simply Wall St VC/PE category (2025)

Lin Xiaoyi

11,880,000

~1.3

Placement participation, 3 Jul 2025

Australia West Holdings Pty Ltd

10,550,000

~1.2

Placement participation, 3 Jul 2025

Australia North Holdings Pty Ltd

10,002,433

~1.1

Placement participation, 3 Jul 2025

Competitive Landscape

Competitors by Segment

Business lineCompetitorHQCompeting product(s)Relative positioning vs Atomo

HIV self-test

OraSure Technologies (NASDAQ: OSUR)

US

OraQuick HIV Self-Test (oral fluid)

Market leader in HIV self-testing; oral sample avoids finger-stick; far larger scale

HIV self-test / professional

Abbott Laboratories (NYSE: ABT)

US

Determine HIV, other rapid tests (ex-Alere)

Dominant global rapid test supplier; scale, tender pricing power

HIV self-test / professional

bioLytical Laboratories

Canada

INSTI HIV Self Test and professional test

Direct blood-based self-test competitor in developed markets and LMICs

HIV self-test (Europe)

Biosynex (Euronext Growth)

France

Exacto / autotest VIH

Direct European retail competitor; also owns Chembio

HIV / syphilis

Chembio Diagnostics (now part of Biosynex)

US

DPP HIV-Syphilis, DPP Syphilis Screen & Confirm

Combined treponemal/non-treponemal syphilis capability competes with Atomo's Active Syphilis

HIV / syphilis

Trinity Biotech (NASDAQ: TRIB)

Ireland

Uni-Gold HIV, syphilis rapid tests

Professional HIV rapid tests in LMIC tenders

HIV / syphilis / broad RDT

SD Biosensor

South Korea

SD Bioline HIV, syphilis and duo tests

Low-cost high-volume Asian RDT manufacturer

Broad RDT / LMIC

Premier Medical Corporation, Wondfo, other Asian manufacturers

India / China

HIV and syphilis RDTs

Price competition in donor-funded tenders

OEM lateral-flow devices and contract manufacturing

Abingdon Health

UK

Lateral-flow contract development and manufacturing

Competes for OEM partners seeking development and manufacturing

Integrated sample-to-result POC devices

Various (e.g., in-house cassette designs at IVD companies)

Global

Proprietary cassettes, capillary collection devices

Partners may develop in-house rather than license Pascal

Peer Comparison FY2026

MetricAtomo (FY2026, AUD)OraSure (FY2024, USD)Abbott (FY2024, USD)

Revenue

A$5.3m

~US$186m

~US$42bn (group)

Revenue growth

+41%——

Gross margin

35%——

R&D intensity (P&L line)

14%——

Profitability

Loss-making

—

Profitable

Recent Developments

--

Company Snapshot

$3.4M

Revenue

$12M

Market Cap

2010

Founded

Leichhardt, Australia

Headquarters

SWOT Analysis

Strengths

  • Regulatory validation of the platform. FDA CLIA waiver for FebriDx on Pascal (March 2026), based on more than 99% trained/untrained concordance (FY2026 Results Overview).
  • Accelerating revenue. FY2026 revenue up 41% to A$5.33m; Q4 FY2026 revenue A$2.3m was the strongest quarter in the period reviewed (Q4 FY2026 4C).
  • OEM traction. OEM revenue up 209% to A$2.15m; FebriDx Pascal orders ~A$1.9m, nine times FY2025 (FY2026 Annual Report).
  • Approved finished product with global access. HIV Self-Test has WHO PQ, TGA and CE status; HIV revenue up 21% to A$2.84m.
  • Debt-free balance sheet with A$3.71m cash and no financing facilities required (Note 21).
  • Non-dilutive funding capability. A$2.15m of R&D rebate and grant income in FY2026; A$2.44m CRC-P grant executed (Note 4; Oct 2025 release).
  • Cost discipline. Third consecutive year of overhead reduction; professional fees down 48% (FY2026 Results Overview).

Weaknesses

  • Customer concentration. 92.0% of FY2026 revenue from five customers; the largest is 36.2% (Note 1).
  • Gross margin compression from 51% to 35%; core product margin down from 42% to 35% (FY2026 Results Overview).
  • Rising cash burn. Operating cash outflow of A$3.37m versus A$1.96m in FY2025 (Statement of Cash Flows).
  • Persistent losses. Accumulated losses of A$68.5m; the last statutory profit is not on record in sources reviewed (Statement of Financial Position).
  • Ageing asset base. Plant and equipment 98% depreciated (A$7.21m cost, A$7.09m accumulated depreciation, Note 10); reinvestment required.
  • Thin governance bench. Three-person board; the only committee includes the Interim CEO (FY2026 Remuneration Report).
  • Weak retail investor support. The May 2026 SPP raised A$44.5k of a A$1.0m target (ASX 15 May 2026).

Opportunities

  • FebriDx US ramp. The Lumos–PHASE contract is valued at up to ~US$316m of FebriDx revenue over six years subject to MOQs; each test requires a Pascal cassette (FY2026 Annual Report).
  • CLIA predicate for new partners. Chromacare is considering a US CLIA waiver submission using FebriDx as predicate (FY2026 Results Overview).
  • New OEM supply agreements with the UK customer (20,000 validation units ordered), Chromacare and two new customers, anticipated early FY2027.
  • Pharmacy expansion. Targets of 6× in Australia (from 196) and 8× in New Zealand (from 73) over three years.
  • Active Syphilis. Sensitivity above 85% claimed market-leading; uses existing HIV channels; clinical trials from early CY2027.
  • Margin uplift from in-house blistering and high-cavitation tooling (FY2026 Annual Report).
  • ALT liver test addresses DILI monitoring and fatty liver screening, with possible government funding.

Threats

  • Partner execution risk. Atomo's OEM revenue depends on Lumos and PHASE meeting MOQs; contract value is "subject to Lumos achieving the contract's minimum order quantities."
  • Global health funding volatility affecting Global Fund–financed procurement (LMIC orders, Jan–Feb 2026).
  • Dilution. 230.5m options outstanding (~25.5% of shares) plus likely future raises.
  • Leadership instability. Founder-CEO departed in August 2026; the interim CEO's term is 6 months (extendable by 6 months).
  • Competitive pressure from Abbott, OraSure, bioLytical, Biosynex and low-cost Asian RDT makers in HIV and syphilis.
  • Regulatory risk across TGA, FDA, IVDR, WHO PQ and Health Canada (FY2026 risk section); IVDR transition is a known burden for EU IVD makers.
  • Disclosure scrutiny. ASX price query (25 March 2026) and Aware Letter (9 April 2026) around the CLIA waiver.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025Placement announced at A$0.0185 with 1:1 attaching options (A$0.04, 3 years)Funding after FY2025 cash decline
2 May 2025Patrick Cook and Anthony May join board; Keith, Kasian and Neff resignBoard refresh with IVD industry expertise
23 May 2025John Kelly appointed Interim ChairTemporary combination of Chair and CEO
26 Jun 2025EGM approves tranche 2 placement and SPP shortfall placementEnables completion of raise
3 Jul 2025Tranche 2: 31.7m shares issued (~A$567k)Capital
Jul 2025Lumos–PHASE six-year exclusive US FebriDx agreement; Atomo exclusive Pascal supplierTransformational OEM opportunity
24 Jul 2025SPP shortfall tranche 1: 16.8m shares (A$311k)Capital
Jul 2025 (Q4 FY2025 report)Australian HIV Self-Test sales +143%; A$2.6m new capital securedHIV momentum
14 Aug 2025Final SPP shortfall: 22.5m shares (A$416.6k)Capital
29 Aug 2025FY2025 Annual Report: revenue A$3.79m, net loss A$4.97m, gross margin 51%Baseline year
9 Sep 2025Patrick Cook appointed independent ChairGovernance normalised
Q1 FY2026Lumos submits FebriDx CLIA waiver application to FDA; Lumos Pascal orders ~A$1mRegulatory catalyst set up
Oct 2025HIV Self-Test launched on Chemist Warehouse e-commerce; Florey shown at two US POC conferencesChannel and OEM expansion
29 Oct 2025Q1 FY2026 4C: revenue A$680k; cash A$3.39m; preliminary syphilis data with high specificityQuarterly update
12 Dec 2025Options granted to NEDs (A$0.012 exercise, expiring 30 Jun 2028)Board incentives
Q2 FY2026Exclusive licence for liver function (ALT) test; FebriDx Pascal order A$495k; Global Fund HIV order A$500kPipeline and orders
15 Jan 2026A$502k Global Fund–financed HIV Self-Test order (Mylan brand, African country)Material order
Jan 2026Pascal orders from two new OEM customersOEM diversification
28 Jan 2026Q2 FY2026 4C: revenue A$1.5m (+121% QoQ); cash A$3.51m; no debtStrong quarter
30 Jan 2026Second Global Fund order: A$416kMaterial order
6 Feb 2026Further HIV Self-Test order: A$630kMaterial order
26 Feb 2026H1 FY2026: revenue A$2.18m (+6%); loss after tax A$1.76m (-36%)Interim results
25 Mar 2026ASX price query; Atomo says it is unaware of FDA outcome while Lumos is in haltDisclosure scrutiny
26 Mar 2026Atomo enters trading halt—
27 Mar 2026Lumos announces FDA CLIA waiver for FebriDxKey regulatory catalyst achieved
30 Mar 2026Atomo confirms CLIA waiver ("unlocks upside for Pascal"); A$3.0m placement at A$0.033 plus SPP up to A$1.0m (1-for-2 options at A$0.045)Funding; share price A$0.040
9 Apr 2026ASX Aware Letter issuedRegulatory query
16 Apr 2026SPP prospectus despatched—
17 Apr 2026Response to ASX Aware Letter; Atomo states compliance with Listing Rule 3.1Disclosure matter closed by response
28 Apr 2026Q3 FY2026 4C: revenue A$814k; YTD ~A$3.0m (+4%); cash A$2.6m; orders above A$2mSoft quarter, strong orders
15 May 2026SPP results: only A$44.5k raised (1.35m shares) against A$1.0m targetWeak retail support
29 May 2026Change in substantial holding lodgedRegister change
1 Jul 2026Notification of cessation of securitiesOption lapse
23 Jul 2026Q4 FY2026 4C: quarterly revenue A$2.3m; FY A$5.3m (+40%); cash A$3.7m; orders above A$1.5m; Australian pharmacies +33% in quarter; new blister machine set upRecord quarter
24 Jul 2026Q4 FY2026 investor webinar—
19 Aug 2026John Kelly steps down; Dr Cheri Walker Interim CEO; global CEO search beginsLeadership change
31 Aug 2026FY2026 Annual Report, Results Overview and Corporate Governance Statement releasedAnnual results
17 Sep 2026Deadline for director nominations for AGMPossible board additions
24 Sep 2026Strategy Update and FY2026 investor webinar–
~5 Nov 2026 (upcoming)Annual General MeetingRemuneration and board votes

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Income Statement: Revenue & Gross Profit: Revenue fell from AUD 12.3 Mn in FY2022 to AUD 5.3 Mn in FY2026.
Atomo Diagnostics Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue12.32.54.13.85.3
Cost of sales8.11.92.71.93.5
Gross profit4.30.71.41.91.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.